Perflutren

DRUG4 trials

Sponsors

Novartis Pharma AG, University of Virginia, Stanford University, Thomas Jefferson University

Conditions

Carotid AtherosclerosisColon CancerContrast Induced Acute Kidney InjuryLiver MetastasesSjögren's syndrome

Phase 2

An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome

CompletedCTIS2023-508957-24-00

Novartis Pharma AGSjögren's syndrome

Start: 2022-07-27End: 2026-01-05Target: 20Updated: 2025-04-29

Phase 4

Risk Assessment of Carotid Plaques Using 3D Contrast-Enhanced Ultrasound

Active, not recruitingNCT04643431

Thomas Jefferson UniversityCarotid Atherosclerosis

Start: 2020-12-01End: 2025-12-31Updated: 2025-04-24

Unknown Phase

Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram

University of VirginiaContrast Induced Acute Kidney Injury

Start: 2012-02-29Target: 150Updated: 2013-12-19

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

CompletedNCT01631318

Stanford UniversityColon Cancer, Liver Metastases

Start: 2012-11-01End: 2020-09-30Updated: 2022-06-10